IRD$4.16
$4.1483
Chart
Performance
Key Stats
AI IRD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldOpus Genetics (IRD) is a clinical-stage biopharmaceutical company focused on inherited retinal diseases. While its thematic potential in addressing unmet medical needs is significant, current financial performance, valuation, and technical indicators suggest a neutral to cautious outlook. The company operates in a high-risk, high-reward sector, and further clinical trial success and revenue generation are critical for long-term value realization.
Thematic
Opus Genetics operates within the rapidly advancing field of gene therapy for rare diseases, specifically inherited retinal diseases (IRDs). The unmet medical need in this area is substantial, and successful development of its pipeline therapies could lead to significant market penetration. However, the inherent risks in clinical-stage biopharmaceutical development, including trial failures and regulatory hurdles, temper the thematic score.
Fundamental
Opus Genetics is a clinical-stage biopharmaceutical company with no revenue generation from product sales. Its financial health is characterized by significant net losses and negative earnings per share, typical for its stage. The company relies on financing activities to fund its operations. While it holds substantial cash reserves, continued cash burn necessitates future fundraising, which carries dilution risk.
Technical
The stock price of Opus Genetics (IRD) has experienced significant volatility, reflecting its development stage and market sentiment. Current technical indicators suggest a neutral to slightly bearish short-term outlook. The price is trading below key moving averages, and oscillators are mixed, indicating a lack of strong directional conviction.
| Factor | Score |
|---|---|
| Ophthalmic Gene Therapy Market | 80 |
| Pipeline Development Stage | 60 |
| Competition Landscape | 65 |
| Regulatory Environment for Gene Therapy | 75 |
| Partnerships and Collaborations | 50 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 0 |
| Balance Sheet Health | 60 |
| Cash Flow | 10 |
| Earnings Per Share (EPS) | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 50 |
| Moving Averages (Longer Term) | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
The company has exceeded earnings per share (EPS) estimates in the last two reported quarters (2025 Q1 and 2025 Q2), indicating improving operational efficiency and profitability.
Strong Cash Position
As of Q1 2025, the company holds $41.8 million in cash and cash equivalents, providing a significant buffer and flexibility for future investments and operations.
Bearish Points (8)
Consistent Net Losses
The company has reported significant net losses in the trailing twelve months (TTM) and annual periods (2023, 2024), with a negative net margin indicating unprofitability.
Negative Earnings Per Share (EPS)
EPS (TTM) is reported at -2.1, and quarterly EPS estimates and reported figures are consistently negative, highlighting a lack of profitability on a per-share basis.
Calendar
November 2020
6
Next Dividend Date
August 2025
11
Next Earnings Date
H: $-0.26
A: $-0.26
L: $-0.26
H: 4.50M
A: 4.27M
L: 4.00M
Profile
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Seasonals
Price Target
6.00 USD
The 39 analysts offering 1 year price forecasts for IRD have a max estimate of 8.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader in providing investment decision support tools, including equity indices, portfolio risk and performance analytics, and ESG data. Directly core to investment research and risk management.
Weight: 90
Premier provider of credit ratings, financial benchmarks (S&P Dow Jones Indices), and financial information through its Market Intelligence division. Essential for market data and research.
Weight: 88
Provides integrated financial information and analytical applications to the global investment community, covering market data, company financials, and portfolio analysis. Directly aligned with investment research.
Weight: 85
Offers independent investment research, ratings, and data for a wide range of investment vehicles including mutual funds, ETFs, and stocks. Central to investment research and due diligence.